The first prototype in Figure 1 is the basket trial of vemurafenib.2 Vemurafenib is an oral inhibitor of BRAF that has greater selectivity for the BRAFV600 mutant form of the kinase than for wild-type BRAF, which had been previously approved for patients with BRAFV600E mutation–positive metastatic melanoma. Here, BRAF is linked to metastatic melanoma.